Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medical device company Angiotech Pharmaceuticals has submitted a 510(k) application to the FDA for its anti-infective 5-fluorouracil-coated central venous catheter.
Subscribe to our email newsletter
Pending the receipt of all necessary regulatory approvals, Angiotech anticipates launching the commercial 5-fluorouracil-coated (5-FU) central venous catheter (CVC) product line in 2008.
William Hunter, president and CEO of Angiotech, said: “We are pleased to complete the submission of a 510(k) application to the FDA for our 5-FU CVC, as we believe this represents another important step towards commercializing this product line and developing our 5-FU anti-infective platform.”